Effectiveness of ACZ885 in Treating Joint Inflammation in Rheumatoid Arthritis
Author Information
Author(s): Alten Rieke, Gram Hermann, Joosten Leo A, Berg Wim B van den, Sieper Joachim, Wassenberg Siegfrid, Burmester Gerd, van Riel Piet, Diaz-Lorente Maria, Bruin Gerardus JM, Woodworth Thasia G, Rordorf Christiane, Batard Yannik, Wright Andrew M, Jung Thomas
Primary Institution: Schlosspark-Klinik Teaching Hospital Charité University Medicine Berlin
Hypothesis
Can the human anti-IL-1β monoclonal antibody ACZ885 effectively reduce joint inflammation in rheumatoid arthritis patients?
Conclusion
ACZ885 showed clinical improvement in some patients with rheumatoid arthritis, indicating its potential effectiveness.
Supporting Evidence
- ACZ885 can completely suppress IL-1β-mediated joint inflammation in mice.
- In a proof-of-concept study, 32 patients were enrolled and treated with ACZ885.
- Clinical improvement was observed in the 10 mg/kg treatment group at week 6.
- A statistically significant reduction in disease activity score was noted after 4 weeks in the 10 mg/kg group.
- C-reactive protein levels decreased in patients treated with ACZ885 within 1 week.
Takeaway
ACZ885 is a new medicine that helps some people with arthritis feel better by reducing inflammation in their joints.
Methodology
The study involved a randomized, double-blind, placebo-controlled, dose escalation design with patients receiving different doses of ACZ885.
Potential Biases
Potential bias in patient selection and assessment methods.
Limitations
The small sample size limits the ability to draw definitive conclusions about efficacy and safety.
Participant Demographics
Patients with active rheumatoid arthritis, mean age around 61 years, with a history of treatment with methotrexate.
Statistical Information
P-Value
0.085
Statistical Significance
p=0.085
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website